Gallego Carlos J, Perez Matthew L, Burt Amber, Amendola Laura M, Shirts Brian H, Pritchard Colin C, Hisama Fuki M, Bennett Robin L, Veenstra David L, Jarvik Gail P
Department of Medicine, Division of Medical Genetics, University of Washington, 1705 NE Pacific Street, K228, UW Box 357720, Seattle, WA, 98195, USA.
Department of Pharmacy, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, 98195, USA.
J Genet Couns. 2016 Jun;25(3):515-9. doi: 10.1007/s10897-015-9902-0. Epub 2015 Dec 5.
Next generation sequencing (NGS) gene panels are increasingly used in medical genetics clinics for the evaluation of common inherited cancer syndromes, but the clinical efficacy of these tests, and the factors driving clinical providers to order them are unclear. We conducted a patterns-of-care study to compare patients evaluated with NGS gene panels with a reference group. We abstracted demographic, socioeconomic, and clinical information in a retrospective cohort of patients referred to a large medical genetics clinic for evaluation of inherited colorectal cancer and polyposis syndromes. Patients tested with NGS gene panels were more likely to be insured compared to the reference group (85.3 % vs. 69.2 %, p = 0.0068),less likely to have prior tumor tissue testing (29.4 % vs. 54.3 %, p = 0.0004), and less likely to have an abnormal tumor tissue test result (46.7 % vs. 74.5 %, p = 0.01). No significant differences were found between groups in age, gender, race, employment status, personal history of colorectal cancer, or proportion of patients fulfilling Lynch syndrome clinical criteria. Patients with NGS testing were less likely to have a pathogenic/likely pathogenic variant detected (13.7 % vs. 31.9 %, p = 0.002). Patients referred for NGS testing to evaluate inherited colorectal cancer/polyposis risk appear to undergo tumor tissue testing less frequently than non-NGS testing patients. Further studies are needed to assess the most effective and cost-effective approach to genomic diagnosis in this patient population.
新一代测序(NGS)基因检测板在医学遗传学诊所中越来越多地用于评估常见的遗传性癌症综合征,但这些检测的临床疗效以及促使临床医生开具检测单的因素尚不清楚。我们开展了一项医疗模式研究,以将接受NGS基因检测板评估的患者与一个参照组进行比较。我们在一个回顾性队列中提取了人口统计学、社会经济和临床信息,该队列中的患者被转诊至一家大型医学遗传学诊所,以评估遗传性结直肠癌和息肉病综合征。与参照组相比,接受NGS基因检测板检测的患者更有可能拥有保险(85.3%对69.2%,p = 0.0068),先前进行肿瘤组织检测的可能性较小(29.4%对54.3%,p = 0.0004),且肿瘤组织检测结果异常的可能性较小(46.7%对74.5%,p = 0.01)。两组在年龄、性别、种族、就业状况、结直肠癌个人史或符合林奇综合征临床标准的患者比例方面未发现显著差异。接受NGS检测的患者检测到致病/可能致病变异的可能性较小(13.7%对31.9%,p = 0.002)。转诊接受NGS检测以评估遗传性结直肠癌/息肉病风险的患者进行肿瘤组织检测的频率似乎低于未接受NGS检测的患者。需要进一步开展研究,以评估针对该患者群体进行基因组诊断的最有效和最具成本效益的方法。